Literature DB >> 11357954

Cellular and humoral immune response in progressive multifocal leukoencephalopathy.

F Weber1, C Goldmann, M Krämer, F J Kaup, M Pickhardt, P Young, H Petry, T Weber, W Lüke.   

Abstract

Progressive multifocal leukoencephalopathy (PML) is a fatal, demyelinating disease caused by JC virus (JCV) in patients with severe immunosuppression. We studied the JCV-specific cellular and humoral immune response in 7 healthy donors (HD), 6 human immunodeficiency virus-1 (HIV-1)-infected patients without PML (HIV), 4 HIV-1-negative patients with PML (PML), and 8 HIV-1-positive patients with PML (HIV/PML). As antigens, recombinant virus-like particles of the major structural protein VP1 (VP1-VLP) of JCV, tetanus toxoid (TT), or the mitogen phytohemagglutinin (PHA) were used. Proliferation of peripheral blood mononuclear cells (PBMC) after stimulation with the VP1-VLP was significantly suppressed in PML and HIV/PML patients compared to HD. After antigen stimulation the production of interferon-gamma (IFN-gamma) was reduced in PML, in HIV/PML, and in HIV patients. The production of interleukin-10 (IL-10), however, was elevated in HIV/PML patients. Neither proliferation nor cytokine production correlated with the presence of JCV DNA in PBMC. The immunoglobulin G serum antibody titer to the VP1-VLP was slightly elevated in HIV, elevated in PML, and highly elevated in HIV/PML patients compared to HD. The development of PML appears to coincide with a general impairment of the Th1-type T-helper cell function of cell-mediated immunity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11357954

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  44 in total

1.  A controlled inflammation and a regulatory immune system are associated with more favorable prognosis of progressive multifocal leukoencephalopathy.

Authors:  Nobuo Sanjo; Yurie Nose; Yukiko Shishido-Hara; Saneyuki Mizutani; Yoshiki Sekijima; Hitoshi Aizawa; Toru Tanizawa; Takanori Yokota
Journal:  J Neurol       Date:  2018-12-03       Impact factor: 4.849

Review 2.  Progressive multifocal leukoencephalopathy and newer biological agents.

Authors:  Joseph R Berger
Journal:  Drug Saf       Date:  2010-11-01       Impact factor: 5.606

Review 3.  Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis.

Authors:  Chen S Tan; Igor J Koralnik
Journal:  Lancet Neurol       Date:  2010-04       Impact factor: 44.182

Review 4.  Progressive multifocal leukoencephalopathy.

Authors:  Joseph R Berger
Journal:  Curr Neurol Neurosci Rep       Date:  2007-11       Impact factor: 5.081

5.  High incidence of JC viruria in JC-seropositive older individuals.

Authors:  Han Chang; Meilin Wang; Rong-Tai Tsai; Hui-Sheng Lin; Jin-Shue Huan; Wen-Chuang Wang; Deching Chang
Journal:  J Neurovirol       Date:  2002-10       Impact factor: 2.643

Review 6.  Update on progressive multifocal leukoencephalopathy.

Authors:  Israel Steiner; Joseph R Berger
Journal:  Curr Neurol Neurosci Rep       Date:  2012-12       Impact factor: 5.081

Review 7.  Progressive Multifocal Leukoencephalopathy Following Treatment with Rituximab in an HIV-Negative Patient with Non-Hodgkin Lymphoma. A Case Report and Literature Review.

Authors:  Valentina Felli; Alessandra Di Sibio; Monica Anselmi; Antonio Gennarelli; Patrizia Sucapane; Alessandra Splendiani; Alessia Catalucci; Carmine Marini; Massimo Gallucci
Journal:  Neuroradiol J       Date:  2014-12-01

Review 8.  Progressive multifocal leukoencephalopathy in HIV-1 infection.

Authors:  Paola Cinque; Igor J Koralnik; Simonetta Gerevini; Jose M Miro; Richard W Price
Journal:  Lancet Infect Dis       Date:  2009-10       Impact factor: 25.071

9.  JC virus-specific immune responses in human immunodeficiency virus type 1 patients with progressive multifocal leukoencephalopathy.

Authors:  Nina Khanna; Marcel Wolbers; Nicolas J Mueller; Christian Garzoni; Renaud A Du Pasquier; Christoph A Fux; Pietro Vernazza; Enos Bernasconi; Raphael Viscidi; Manuel Battegay; Hans H Hirsch
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

Review 10.  Immune surveillance and response to JC virus infection and PML.

Authors:  Sarah Beltrami; Jennifer Gordon
Journal:  J Neurovirol       Date:  2013-12-03       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.